LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced the filing of its first-quarter 2026 Form 10-Q, highlighting continued advancement of its lead oncology candidate, LB-100, including expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. The company also cited continued growth at its recently acquired Liora Technologies Europe subsidiary as it pursues broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
LB-100, a first-in-class clinical PP2A inhibitor, has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. For more information about LIXTE, visit www.lixte.com. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT. To view the full press release, visit https://ibn.fm/oHzhK.
